Heart Rhythm

Hearts should have normal rhythm to their beats, but when these beats are out of synch, it causes inefficient pumping of blood. Irregular heart arrhythmias occur when the electrical signals that coordinate the heart's beats do not work properly. This can cause beats that are too fast (tachycardia), or too slow (bradycardia). Tachycardias include atrial fibrillation (AFib), supraventricular tachycardia, ventricular fibrillation, and ventricular tachycardia (VT). Bradycardias include sick sinus syndrome and conduction block. Electrophysiology arrhythmia treatments include medications, life style changes, and the EP lab interventions of catheter ablation, and implantable pacemakers or defibrillators.

Thumbnail

FDA clears new cardiac mapping solution for treating arrhythmias

The platform provides users with full 3D maps of a patient's heart. 

Thumbnail

Apixaban linked to lower bleeding risk than rivaroxaban for patients with nonvalvular AFib

A new meta-analysis compared outcomes associated with the two popular DOACs. 

Thumbnail

DOACs underprescribed among high-risk AFib patients

The study found that frail patients with AFib are less likely to be treated with DOAC therapy.

Metoprolol demonstrates value as a treatment for obstructive hypertrophic cardiomyopathy

The small study, published in the Journal of the American College of Cardiology, compared patient outcomes associated with metoprolol and a placebo. 

Thumbnail

‘Surprising’ trends in ICD use among HCM patients

ICD use among this patient population is slowly growing, but some key disparities remain.

Doctor patient with masks

Predicting AFib recurrence after catheter ablation remains a challenge

Researchers evaluated 11 different prediction models, and each one fell short.

Thumbnail

Elevated heart rate tied to a greater risk of dementia

The study included more than 2,000 older adults who were followed for up to 12 years.

DOACs outperform VKAs among cardiac amyloidosis patients with HF, AFib

Outcomes from patients prescribed apixaban, rivaroxaban or dabigatran were compared with outcomes from patients given warfarin.